Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1971 1
1972 1
1973 2
1974 3
1975 3
1976 4
1977 2
1978 1
1979 6
1980 2
1981 8
1982 2
1983 3
1984 5
1985 4
1986 4
1987 3
1988 8
1989 11
1990 6
1991 8
1992 7
1993 5
1994 7
1995 2
1996 5
1997 6
1998 8
1999 4
2000 5
2001 5
2002 10
2003 6
2004 5
2005 7
2006 5
2007 9
2008 9
2009 9
2010 8
2011 8
2012 15
2013 10
2014 10
2015 6
2016 10
2017 12
2018 3
2019 6
2020 11
2021 15
2022 12
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Results by year

Filters applied: . Clear all
Page 1
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses.
Nanayakkara N, Curtis AJ, Heritier S, Gadowski AM, Pavkov ME, Kenealy T, Owens DR, Thomas RL, Song S, Wong J, Chan JC, Luk AO, Penno G, Ji L, Mohan V, Amutha A, Romero-Aroca P, Gasevic D, Magliano DJ, Teede HJ, Chalmers J, Zoungas S. Nanayakkara N, et al. Among authors: owens dr. Diabetologia. 2021 Feb;64(2):275-287. doi: 10.1007/s00125-020-05319-w. Epub 2020 Dec 14. Diabetologia. 2021. PMID: 33313987 Free PMC article.
Insulin analogues.
Barnett AH, Owens DR. Barnett AH, et al. Among authors: owens dr. Lancet. 1997 Jan 4;349(9044):47-51. doi: 10.1016/S0140-6736(96)06032-1. Lancet. 1997. PMID: 8988131 Review. No abstract available.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Among authors: owens dr. Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2. Lancet. 2021. PMID: 34863358 Free PMC article. Clinical Trial.
Insulin glargine.
Bolli GB, Owens DR. Bolli GB, et al. Among authors: owens dr. Lancet. 2000 Aug 5;356(9228):443-5. doi: 10.1016/S0140-6736(00)02546-0. Lancet. 2000. PMID: 10981882 No abstract available.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Liu X, Munro APS, Wright A, Feng S, Janani L, Aley PK, Babbage G, Baker J, Baxter D, Bawa T, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Fox L, Qureshi E, Goodman AL, Green CA, Haughney J, Hicks A, Jones CE, Kanji N, van der Klaauw AA, Libri V, Llewelyn MJ, Mansfield R, Maallah M, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Belhadef HT, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Saralaya D, Sharma S, Sheridan R, Stokes M, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Cornelius V, Snape MD, Faust SN; COV-BOOST study group. Liu X, et al. Among authors: owens dr. J Infect. 2023 Jul;87(1):18-26. doi: 10.1016/j.jinf.2023.04.012. Epub 2023 Apr 20. J Infect. 2023. PMID: 37085049 Free PMC article. Clinical Trial.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Ramasamy MN, et al. Among authors: owens dr. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19. Lancet. 2021. PMID: 33220855 Free PMC article. Clinical Trial.
Insulins today and beyond.
Owens DR, Zinman B, Bolli GB. Owens DR, et al. Lancet. 2001 Sep 1;358(9283):739-46. doi: 10.1016/S0140-6736(01)05842-1. Lancet. 2001. PMID: 11551598 Review.
Insulin preparations with prolonged effect.
Owens DR. Owens DR. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S5-14. doi: 10.1089/dia.2011.0068. Diabetes Technol Ther. 2011. PMID: 21668337 Review.
Screening for diabetic retinopathy.
Owens DR, Dolben J, Young S, Ryder RE, Jones IR, Vora J, Jones D, Morsman D, Hayes TM. Owens DR, et al. Diabet Med. 1991;8 Spec No:S4-10. doi: 10.1111/j.1464-5491.1991.tb02148.x. Diabet Med. 1991. PMID: 1825956 Review.
305 results